ArticleMicrobiology spectrum2022
Phenotypic and Genotypic Characterization of a Hypervirulent Carbapenem-Resistant Klebsiella pneumoniae ST17-KL38 Clinical Isolate Harboring the Carbapenemase IMP-4.
Article in Microbiology spectrum, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 25 citations in OpenAlex.
- Hypervirulent and Drug-ResistantInternational journal of general medicine · 2026Review
- Genetic diversity, biochemical properties, epidemiology, and detection methods of IMP- and VIM-type carbapenemases.Clinical microbiology reviews · 2025Review
- Adaptive attenuation of virulence mediated by Wzc mutation in ST11-KL47 Carbapenem-resistantFrontiers in cellular and infection microbiology · 2025Article
- Emergence and evolution of rare ST592Frontiers in cellular and infection microbiology · 2025Article
- Transferable AmpCs inAntimicrobial agents and chemotherapy · 2024Article
- Genome sequencing unveilsmSystems · 2024Article
- In vitro Synergistic and Bactericidal Effects of Aztreonam in Combination with Ceftazidime/ Avibactam, Meropenem/Vaborbactam and Imipenem/Relebactam Against Dual-Carbapenemase-ProducingInfection and drug resistance · 2024Article
- Carbapenemase-ProducingAntibiotics (Basel, Switzerland) · 2023Article
- Convergence of plasmid-mediated Colistin and Tigecycline resistance inFrontiers in microbiology · 2023Article
- Emergence of high-level colistin resistance mediated by multiple determinants, includingFrontiers in cellular and infection microbiology · 2023Article
- Insights on the performance of phenotypic tests versus genotypic tests for the detection of carbapenemase-producing Gram-negative bacilli in resource-limited settings.BMC microbiology · 2022Article
- Epidemiological characteristics and molecular evolution mechanisms of carbapenem-resistant hypervirulentFrontiers in microbiology · 2022Review
- Whole genome sequencing of OXA-232-producingFrontiers in cellular and infection microbiology · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 3 institutions in 2 countries.
Funding
Abstract
Carbapenem-resistant hypervirulent Klebsiella pneumoniae (CR-hvKP) is a threat to global public health. We characterized a sequence type 17 (ST17) K. pneumoniae clinical isolate that was resistant to carbapenems and belonged to serotype KL38/O2. Its complete genome is comprised of a 5.1-Mb chromosome and two conjugative plasmids. The 52,578-bp N-type plasmid pXH210-IMP contains the
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.